1. Volume 121, Issue 5, Pages 1088-1094 (November 2001)
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial 
William J. Sandborn, Stephen B. Hanauer, Seymour Katz, Michael Safdi, Douglas G. Wolf, Richard D. Baerg, William J. Tremaine, Therese Johnson, Nancy N. Diehl, Alan R. Zinsmeister 
Gastroenterology 
Volume 121, Issue 5, Pages (November 2001)
DOI: /gast
Copyright © 2001 American Gastroenterological Association Terms and Conditions

2. Fig. 1
Percentages of patients with Crohn's disease with clinical response or clinical remission, according to treatment group. None of the differences were statistically significant. (A) Clinical response (decrease in CDAI score from baseline ≥70 points). (B) Clinical remission (CDAI score <150 points).
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions

3. Fig. 2
Median scores at each study visit, according to treatment group. None of the differences were statistically significant. (A) CDAI; (B) IBDQ quality of life index.
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions